Lab finder: therascreen FGFR test – the companion diagnostic for BALVERSA (erdafitinib)

Companion diagnostics analyze a patient's DNA or RNA for actionable genetic alterations in order to help determine what treatment options may be best. Companion diagnostics are:

  • FDA-approved for IVD use
  • Sensitive tests that are clinically validated for specific targeted therapies for specific cancers
Image taken prior to COVID-19.

The therascreen FGFR RGQ RT-PCR Kit is a companion diagnostic test for use as an aid in identifying patients with urothelial cancer for whom treatment with BALVERSA (erdafitinib) may be appropriate.

To find a lab that provides testing using the therascreen FGFR RGQ RT-PCR Kit as a companion diagnostic for BALVERSA (erdafitinib), please see the list of labs below and keep in mind that this resource:

  • Is updated frequently, so continue to check back regularly for the most up-to-date information
  • May not represent all of the labs that offer the therascreen FGFR test
  • May not represent each location of the lab organizations below, contact the lab of interest to find the nearest location

If you are a lab that offers the therascreen FGFR test and don’t see your lab listed below, please contact your QIAGEN sales representative or contact QIAGEN at 800-426-8157, option 1.

Labs that provide the therascreen test for FGFR alterations as a companion diagnostic for BALVERSA (erdafitinib)
QIAGEN has a broad portfolio of companion diagnostic products in development.
The therascreen FGFR RGQ RT-PCR Kit is for in vitro diagnostic use.
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm